Frank van Haren

Frank van Haren

Auto-generated profile, based on publicly available information

Frank van Haren

College of Science and Medicine Australian National University Canberra Australia

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2016 in JAMA
Verified
Journal Article
Open access
PDF file
GBGiacomo Bellani
Giacomo Bellani
JLJohn Laffey
John Laffey
TPTai Pham
Tai Pham
EFEddy Fan
Eddy Fan
LBLaurent Brochard
Laurent Brochard
NTNicolas Terzi
Nicolas Terzi
Quiz Ref ID Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury, associated with increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue.1 Although prior epidemiologic studies have provided substantial insights into ARDS,2-5 there remains limited information about the epidemiology, recognition, management, and outcomes of patients with the ARDS, especially in the era of the current Berlin Definition.1 This definition was constructed empirically and validated using retrospective cohorts1; however, prospective studies of the Berlin Definition have been limited to small numbers of centers and patients.6,7

1 January 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GBGiacomo Bellani
Giacomo Bellani
JLJohn Laffey
John Laffey
TPTai Pham
Tai Pham
FMFabiana Madotto
Fabiana Madotto
EFEddy Fan
Eddy Fan
APAntonio Pesenti
Antonio Pesenti
Rationale: Noninvasive ventilation (NIV) is increasingly used in patients with acute respiratory distress syndrome (ARDS). The evidence supporting NIV use in patients with ARDS remains relatively sparse. Objectives: To determine whether, during NIV, the categorization of ARDS severity based on the PaO2/Fi O2 Berlin criteria is useful. Methods: The LUNG SAFE (Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of patients with ARDS. This substudy examines the current practice of NIV use in ARDS, the utility of the PaO2/Fi O2 ratio in classifying patients receiving NIV, and the impact of NIV on outcome. Measurements and Main Results: Of 2,813 patients with ARDS, 436 (15.5%) were managed with NIV on Days 1 and 2 following fulfillment of diagnostic criteria. Classification of ARDS severity based on PaO2/Fi O2 ratio was associated with an increase in intensity of ventilatory support, NIV failure, and intensive care unit (ICU) mortality. NIV failure occurred in 22.2% of mild, 42.3% of moderate, and 47.1% of patients with severe ARDS. Hospital mortality in patients with NIV success and failure was 16.1% and 45.4%, respectively. NIV use was independently associated with increased ICU (hazard ratio, 1.446 [95% confidence interval, 1.159–1.805]), but not hospital, mortality. In a propensity matched analysis, ICU mortality was higher in NIV than invasively ventilated patients with a PaO2/Fi O2 lower than 150 mm Hg. Conclusions: NIV was used in 15% of patients with ARDS, irrespective of severity category. NIV seems to be associated with higher ICU mortality in patients with a PaO2/Fi O2 lower than 150 mm Hg. Clinical trial registered with www.clinicaltrials.gov (NCT 02010073).

12 April 2016 in JAMA
Verified
Journal Article
Closed access
PDF file
MRMichael C. Reade
Michael C. Reade
GEGlenn M. Eastwood
Glenn M. Eastwood
RBRinaldo Bellomo
Rinaldo Bellomo
MBMichael Bailey
Michael Bailey
ABAndrew Bersten
Andrew Bersten
FGfor the DahLIA Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
for the DahLIA Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Research from JAMA — Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium — A Randomized Clinical Trial

18 October 2016 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
JLJohn Laffey
John Laffey
GBGiacomo Bellani
Giacomo Bellani
TPTai Pham
Tai Pham
EFEddy Fan
Eddy Fan
FMFabiana Madotto
Fabiana Madotto
TGThe LUNG SAFE Investigators and the ESICM Trials Group
The LUNG SAFE Investigators and the ESICM Trials Group
Purpose To improve the outcome of the acute respiratory distress syndrome (ARDS), one needs to identify potentially modifiable factors associated with mortality. Methods The large observational study to understand the global impact of severe acute respiratory failure (LUNG SAFE) was an international, multicenter, prospective cohort study of patients with severe respiratory failure, conducted in the winter of 2014 in a convenience sample of 459 ICUs from 50 countries across five continents. A pre-specified secondary aim was to examine the factors associated with outcome. Analyses were restricted to patients (93.1 %) fulfilling ARDS criteria on day 1–2 who received invasive mechanical ventilation. Results 2377 patients were included in the analysis. Potentially modifiable factors associated with increased hospital mortality in multivariable analyses include lower PEEP, higher peak inspiratory, plateau, and driving pressures, and increased respiratory rate. The impact of tidal volume on outcome was unclear. Having fewer ICU beds was also associated with higher hospital mortality. Non-modifiable factors associated with worsened outcome from ARDS included older age, active neoplasm, hematologic neoplasm, and chronic liver failure. Severity of illness indices including lower pH, lower PaO2/FiO2 ratio, and higher non-pulmonary SOFA score were associated with poorer outcome. Of the 578 (24.3 %) patients with a limitation of life-sustaining therapies or measures decision, 498 (86.0 %) died in hospital. Factors associated with increased likelihood of limitation of life-sustaining therapies or measures decision included older age, immunosuppression, neoplasia, lower pH and increased non-pulmonary SOFA scores. Conclusions Higher PEEP, lower peak, plateau, and driving pressures, and lower respiratory rate are associated with improved survival from ARDS. Trial Registration: ClinicalTrials.gov NCT02010073.

18 April 2015 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
AWA. Wassenaar
A. Wassenaar
Mark van den BoogaardMark van den Boogaard
Mark van den Boogaard
TAT. van Achterberg
T. van Achterberg
ASArjen Slooter
Arjen Slooter
MKM. A. Kuiper
M. A. Kuiper
PPP. Pickkers
P. Pickkers
Rationale Delirium incidence in intensive care unit (ICU) patients is high and associated with poor outcome. Identification of high-risk patients may facilitate its prevention. Purpose To develop and validate a model based on data available at ICU admission to predict delirium development during a patient’s complete ICU stay and to determine the predictive value of this model in relation to the time of delirium development. Methods Prospective cohort study in 13 ICUs from seven countries. Multiple logistic regression analysis was used to develop the early prediction (E-PRE-DELIRIC) model on data of the first two-thirds and validated on data of the last one-third of the patients from every participating ICU. Results In total, 2914 patients were included. Delirium incidence was 23.6 %. The E-PRE-DELIRIC model consists of nine predictors assessed at ICU admission: age, history of cognitive impairment, history of alcohol abuse, blood urea nitrogen, admission category, urgent admission, mean arterial blood pressure, use of corticosteroids, and respiratory failure. The area under the receiver operating characteristic curve (AUROC) was 0.76 [95 % confidence interval (CI) 0.73–0.77] in the development dataset and 0.75 (95 % CI 0.71–0.79) in the validation dataset. The model was well calibrated. AUROC increased from 0.70 (95 % CI 0.67–0.74), for delirium that developed 6 days. Conclusion Patients’ delirium risk for the complete ICU length of stay can be predicted at admission using the E-PRE-DELIRIC model, allowing early preventive interventions aimed to reduce incidence and severity of ICU delirium.

3 December 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
PYPaul Young
Paul Young
MSManoj Saxena
Manoj Saxena
RBRinaldo Bellomo
Rinaldo Bellomo
RFRoss Freebairn
Ross Freebairn
NHNaomi Hammond
Naomi Hammond
RBRichard Beasley
Richard Beasley
Acetaminophen is a common therapy for fever in patients in the intensive care unit (ICU) who have probable infection, but its effects are unknown. We randomly assigned 700 ICU patients with fever (body temperature, ≥38°C) and known or suspected infection to receive either 1 g of intravenous acetaminophen or placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death. The primary outcome was ICU-free days (days alive and free from the need for intensive care) from randomization to day 28. The number of ICU-free days to day 28 did not differ significantly between the acetaminophen group and the placebo group: 23 days (interquartile range, 13 to 25) among patients assigned to acetaminophen and 22 days (interquartile range, 12 to 25) among patients assigned to placebo (Hodges–Lehmann estimate of absolute difference, 0 days; 96.2% confidence interval [CI], 0 to 1; P=0.07). A total of 55 of 345 patients in the acetaminophen group (15.9%) and 57 of 344 patients in the placebo group (16.6%) had died by day 90 (relative risk, 0.96; 95% CI, 0.66 to 1.39; P=0.84). Early administration of acetaminophen to treat fever due to probable infection did not affect the number of ICU-free days. (Funded by the Health Research Council of New Zealand and others; HEAT Australian New Zealand Clinical Trials Registry number, ACTRN12612000513819.)